During the past 13 years, Aurinia Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 55.70% per year. The lowest was -49.50% per year. And the median was 6.40% per year.
Aurinia Pharmaceuticals Price-to-Free-Cash-Flow Historical Data
The historical data trend for Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Aurinia Pharmaceuticals's Share Price of today is $8.00. Aurinia Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Aurinia Pharmaceuticals Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AUPH has been successfully added to your 